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Over the past years, echocardiography has been
shown to play a crucial role in the accurate evaluation
of left ventricular function particularly in patients
suspected for ischemic heart disease [1–3]. The ability
to rapidly perform bedside echocardiography with
Echo-Doppler imaging places this modality in the
heart of clinical research to understand cardiac
function and to quantify various associated abnor-
malities [4–8]. Echocardiography has found a major
niche in visualizing left ventricular function both at
rest and during stress. Widespread use of dobutamine-
echocardiography has contributed to more frequent
recognition of wall motion disturbances due to
coronary artery disease [9–11]. Its applicability in
prognostic assessment of such patients has been
repeatedly confirmed, particularly in diabetic subjects
[12]. Coronary artery disease is the leading cause of
morbidity and mortality in patients with diabetes
mellitus. In fact, patients with diabetes have the same
risk of myocardial infarction as do non-diabetic
subjects with a history of infarction. Present data
indicate a substantially elevated risk of cardiovascular
disease even before a clinical diagnosis of type-2
diabetes has been made. Identifying patients with
diabetes suspected for coronary artery disease who
will benefit from medical and/or invasive intervention
to prevent cardiovascular events is a challenge in both
symptomatic and asymptomatic patients. The decision
to evaluate patients with diabetes who are asymptom-
atic for coronary artery disease presents the greatest
challenge; investigation will reveal 10–15% of these
patients to have coronary artery disease. Current
diagnostic tools include exercise tolerance testing
[13–18], stress myocardial perfusion imaging
[19–26], stress MRI [27–57], and stress echocardiog-
raphy [12].
In the current issue of the International Journal of
Cardiovascular Imaging, Innocenti et al. [58] studied
322 type-2 diabetic patients who underwent dobuta-
mine-stress echocardiography for known or suspected
coronary artery disease. Indications to dobutamine-
stress echocardiography were evaluation of symp-
toms suggesting presence of coronary artery disease
or assessment of known coronary artery disease. End-
points of the study were all-cause mortality, cardiac
death, and non-fatal myocardial infarction. During
dobutamine-stress echocardiography, viability and
inducible ischemia developed in 65 (20%) and 192
(60%) subjects, respectively. Severe ischemia
(defined as an asynergic area including more than
40% of all segments combined with a rate pressure
product \17000) appeared in 88 (27%) of patients.
Presence of diabetic treatment or microvascular
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diabetic complications did not affect prognosis, while
longer diabetes duration was associated with higher
all-cause mortality at univariate analysis. At multi-
variate analysis, advanced age, decreased left ven-
tricular ejection fraction, and peripheral vascular
disease independently determined increased all-cause
mortality. New hard cardiac events occurred more
frequently in presence of peripheral vascular disease,
viability and severe ischemia. The authors concluded
that in diabetic patients with known or suspected
coronary artery disease, presence of viability and
severe ischemia during dobutamine-stress echocardi-
ography are independently associated with a higher
occurrence of hard cardiac events. The clinical
variables showed a weak prognostic role, except for
age and presence of peripheral vascular disease.
These findings emphasize the role of stress echocar-
diography in patients with type-2 diabetes.
It should, however, be realized, that the value of
stress imaging in diabetic patients is dependent on the
presence and nature of symptoms. In symptomatic
patients, myocardial perfusion imaging provides
similar diagnostic and prognostic accuracies as in
patients without diabetes [59]. However, the utility of
screening patients with type-2 diabetes for asymp-
tomatic coronary artery disease remains controversial
[60–62]. For instance, the Detection of Ischemia in
Asymptomatic Diabetics (DIAD) study [62] assessed
whether routine screening for coronary artery disease
identified patients with type-2 diabetes as being at
high cardiac risk and whether it affects their cardiac
outcomes. A total of 1123 participants with type-2
diabetes and no symptoms of coronary artery disease
were randomly assigned to be screened with adeno-
sine-stress radionuclide myocardial perfusion imag-
ing or no screening. It was found that in patients with
diabetes, the cardiac event rates were low and were
not significantly reduced by screening for myocardial
ischemia over almost 5 years. Therefore, findings
from the DIAD study indicate that routine screening
of asymptomatic patients with diabetes is not
justified.
Notwithstanding, the current study [58] shows that
dobutamine-stress echocardiography has a major role
in the evaluation of diabetic patients. In symptomatic
diabetic patients with known or suspected coronary
artery disease, advanced age and reduced left ven-
tricular function are independent predictors of total
mortality. Presence of viability and severe ischemia
during dobutamine-stress echocardiography are inde-
pendently associated with higher occurrence of new
major cardiac events. Therefore, dobutamine-stress
echocardiography is an important prognostic imaging
modality in assessing cardiovascular risk in symp-
tomatic diabetic patients.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction
in any medium, provided the original author(s) and source are
credited.
References
1. Bax JJ, van der Wall EE (2003) Viability assessment:
nuclear imaging vs. dobutamine echocardiography. Int J
Cardiovasc Imaging 19:529–531
2. Bax JJ, Maddahi J, Poldermans D et al (2003) Preoperative
comparison of different noninvasive strategies for pre-
dicting improvement in left ventricular function after cor-
onary artery bypass grafting. Am J Cardiol 92:1–4
3. Bax JJ, Schinkel AF, Boersma E et al (2003) Early versus
delayed revascularization in patients with ischemic car-
diomyopathy and substantial viability: impact on outcome.
Circulation 108(Suppl 1):II39–II42
4. Bleeker GB, Schalij MJ, Boersma E et al (2007) Relative
merits of M-mode echocardiography and tissue Doppler
imaging for prediction of response to cardiac resynchro-
nization therapy in patients with heart failure secondary to
ischemic or idiopathic dilated cardiomyopathy. Am J
Cardiol 99:68–74
5. Bleeker GB, Bax JJ, Fung JW et al (2006) Clinical versus
echocardiographic parameters to assess response to cardiac
resynchronization therapy. Am J Cardiol 97:260–263
6. Bleeker GB, Holman ER, Steendijk P et al (2006) Cardiac
resynchronization therapy in patients with a narrow QRS
complex. J Am Coll Cardiol 48:2243–2250
7. Ypenburg C, Sieders A, Bleeker GB et al (2007) Myo-
cardial contractile reserve predicts improvement in left
ventricular function after cardiac resynchronization ther-
apy. Am Heart J 154:1160–1165
8. Torn M, Bollen WL, van der Meer FJ, van der Wall EE,
Rosendaal FR (2005) Risks of oral anticoagulant therapy
with increasing age. Arch Intern Med 165:1527–1532
9. Ypenburg C, Schalij MJ, Bleeker GB et al (2007) Impact
of viability and scar tissue on response to cardiac resyn-
chronization therapy in ischaemic heart failure patients.
Eur Heart J 28:33–41
10. Ypenburg C, van der Wall EE, Schalij MJ, Bax JJ (2008)
Imaging in cardiac resynchronisation therapy. Neth Heart J
16:S36–S40
11. Nemes A, Geleijnse ML, van Geuns RJ et al (2008)
Dobutamine stress MRI versus threedimensional contrast
echocardiography: it’s all black and white. Neth Heart J
16:217–218
12. Bigi R, Desideri A, Cortigiani L, Bax JJ, Celegon L,
Fiorentini C (2001) Stress echocardiography for risk
940 Int J Cardiovasc Imaging (2011) 27:939–942
123
stratification of diabetic patients with known or suspected
coronary artery disease. Diabetes Care 24:1596–1601
13. van der Laarse A, Kerkhof PL, Vermeer F et al (1988)
Relation between infarct size and left ventricular perfor-
mance assessed in patients with first acute myocardial
infarction randomized to intracoronary thrombolytic ther-
apy or to conventional treatment. Am J Cardiol 61:1–7
14. Posma JL, Blanksma PK, van der Wall EE, Hamer HP,
Mooyaart EL, Lie KI (1996) Assessment of quantitative
hypertrophy scores in hypertrophic cardiomyopathy:
magnetic resonance imaging versus echocardiography. Am
Heart J 132:1020–1027
15. Pluim BM, Beyerbacht HP, Chin JC et al (1997) Com-
parison of echocardiography with magnetic resonance
imaging in the assessment of the athlete’s heart. Eur Heart
J 18:1505–1513
16. van der Wall EE, den Hollander W, Heidendal GA, Wes-
tera G, Majid PA, Roos JP (1981) Dynamic myocardial
scintigraphy with 123I-labeled free fatty acids in patients
with myocardial infarction. Eur J Nucl Med 6:383–389
17. Braun S, van der Wall EE, Emanuelsson S, Kobrin I (1996)
Effects of a new calcium antagonist, mibefradil (Ro 40–
5967), on silent ischemia in patients with stable chronic
angina pectoris: a multicenter placebo-controlled study.
The mibefradil international study group. J Am Coll Car-
diol 27:317–322
18. de Nooijer R, Verkleij CJ, von der Thu¨sen JH et al (2006)
Lesional overexpression of matrix metalloproteinase-9
promotes intraplaque hemorrhage in advanced lesions but
not at earlier stages of atherogenesis. Arterioscler Thromb
Vasc Biol 26:340–346
19. Bakx AL, van der Wall EE, Braun S, Emanuelsson H,
Bruschke AV, Kobrin I (1995) Effects of the new calcium
antagonist mibefradil (Ro 40–5967) on exercise duration in
patients with chronic stable angina pectoris: a multicenter,
placebo-controlled study. Ro 40–5967 International Study
Group. Am Heart J 130:748–757
20. van der Hoeven BL, Pires NM, Warda HM et al (2005)
Drug-eluting stents: results, promises and problems. Int J
Cardiol 99:9–17
21. van der Laan A, Hirsch A, Nijveldt R et al (2008) Bone
marrow cell therapy after acute myocardial infarction: the
HEBE trial in perspective, first results. Neth Heart J
16:436–439
22. Oosterhof T, Tulevski II, Roest AA et al (2005) Disparity
between dobutamine stress and physical exercise magnetic
resonance imaging in patients with an intra-atrial correc-
tion for transposition of the great arteries. J Cardiovasc
Magn Reson 7:383–389
23. Tulevski II, Hirsch A, Sanson BJ et al (2001) Increased
brain natriuretic peptide as a marker for right ventricular
dysfunction in acute pulmonary embolism. Thromb Hae-
most 86:1193–1196
24. Bax JJ, de Roos A, van Der Wall EE (1999) Assessment of
myocardial viability by MRI. J Magn Reson Imaging
10:418–422
25. van der Meer RW, Rijzewijk LJ, de Jong HW et al (2009)
Pioglitazone improves cardiac function and alters myo-
cardial substrate metabolism without affecting cardiac tri-
glyceride accumulation and high-energy phosphate
metabolism in patients with well-controlled type 2 diabetes
mellitus. Circulation 119:2069–2077
26. Raggi P, Bellasi A, Ratti C (2005) Ischemia imaging and
plaque imaging in diabetes: complementary tools to
improve cardiovascular risk management. Diabetes Care
28:2787–2794
27. Holman ER, Buller VG, de Roos A et al (1997) Detection
and quantification of dysfunctional myocardium by mag-
netic resonance imaging. A new three-dimensional method
for quantitative wall-thickening analysis. Circulation
95:924–931
28. Schuijf JD, Bax JJ, Shaw LJ et al (2006) Meta-analysis of
comparative diagnostic performance of magnetic resonance
imaging and multislice computed tomography for nonin-
vasive coronary angiography. Am Heart J 151:404–411
29. van Rugge FP, van der Wall EE, Bruschke AV (1992) New
developments in pharmacologic stress imaging. Am Heart
J 124:468–485
30. van Rugge FP, Holman ER, van der Wall EE et al (1993)
Quantitation of global and regional left ventricular function
by cine magnetic resonance imaging during dobutamine
stress in normal human subjects. Eur Heart J 14:456–463
31. Pluim BM, Lamb HJ, Kayser HW, Leujes F et al (1998)
Functional and metabolic evaluation of the athlete’s heart
by magnetic resonance imaging and dobutamine stress
magnetic resonance spectroscopy. Circulation 97:666–672
32. van Rugge FP, van der Wall EE, Spanjersberg SJ et al
(1994) Magnetic resonance imaging during dobutamine
stress for detection and localization of coronary artery
disease. Quantitative wall motion analysis using a modi-
fication of the centerline method. Circulation 90:127–138
33. Schuijf JD, Bax JJ, van der Wall EE (2007) Anatomical
and functional imaging techniques: basically similar or
fundamentally different? Neth Heart J 15:43–44
34. Vliegen HW, Doornbos J, de Roos A, Jukema JW, Beke-
dam MA, van der Wall EE (1997) Value of fast gradient
echo magnetic resonance angiography as an adjunct to
coronary arteriography in detecting and confirming the
course of clinically significant coronary artery anomalies.
Am J Cardiol 79:773–776
35. Hoogendoorn LI, Pattynama PM, Buis B, van der Geest RJ,
van der Wall EE, de Roos A (1995) Noninvasive evalua-
tion of aortocoronary bypass grafts with magnetic reso-
nance flow mapping. Am J Cardiol 75:845–848
36. Langerak SE, Vliegen HW, de Roos A et al (2002)
Detection of vein graft disease using high-resolution
magnetic resonance angiography. Circulation 105:328–333
37. Rebergen SA, Ottenkamp J, Doornbos J, van der Wall EE,
Chin JG, de Roos A (1993) Postoperative pulmonary flow
dynamics after Fontan surgery: assessment with nuclear
magnetic resonance velocity mapping. J Am Coll Cardiol
21:123–131
38. Groenink M, Lohuis TA, Tijssen JG et al (1999) Survival
and complication free survival in Marfan’s syndrome:
implications of current guidelines. Heart 82:499–504
39. Niezen RA, Helbing WA, van der Wall EE, van der Geest
RJ, Rebergen SA, de Roos A (1996) Biventricular systolic
function and mass studied with MR imaging in children
with pulmonary regurgitation after repair for tetralogy of
Fallot. Radiology 201:135–140
Int J Cardiovasc Imaging (2011) 27:939–942 941
123
40. Vliegen HW, van Straten A, de Roos A et al (2002)
Magnetic resonance imaging to assess the hemodynamic
effects of pulmonary valve replacement in adults late after
repair of tetralogy of fallot. Circulation 106:1703–1707
41. Oosterhof T, van Straten A, Vliegen HW et al (2007)
Preoperative thresholds for pulmonary valve replacement
in patients with corrected tetralogy of Fallot using car-
diovascular magnetic resonance. Circulation 116:545–551
42. van der Geest RJ, de Roos A, van der Wall EE, Reiber JH
(1997) Quantitative analysis of cardiovascular MR images.
Int J Card Imaging 13:247–258
43. van der Geest RJ, Niezen RA, van der Wall EE, de Roos A,
Reiber JH (1998) Automated measurement of volume flow
in the ascending aorta using MR velocity maps: evaluation
of inter- and intraobserver variability in healthy volunteers.
J Comput Assist Tomogr 22:904–911
44. van der Wall EE, Vliegen HW, de Roos A, Bruschke AV
(1995) Magnetic resonance imaging in coronary artery
disease. Circulation 92:2723–2739
45. Bavelaar-Croon CD, Kayser HW, van der Wall EE et al
(2000) Left ventricular function: correlation of quantitative
gated SPECT and MR imaging over a wide range of val-
ues. Radiology 217:572–575
46. Bax JJ, Lamb H, Dibbets P et al (2000) Comparison of
gated single-photon emission computed tomography with
magnetic resonance imaging for evaluation of left ven-
tricular function in ischemic cardiomyopathy. Am J Car-
diol 86:1299–1305
47. Pluim BM, Chin JC, De Roos A et al (1996) Cardiac
anatomy, function and metabolism in elite cyclists assessed
by magnetic resonance imaging and spectroscopy. Eur
Heart J 17:1271–1278
48. de Roos A, Matheijssen NA, Doornbos J et al (1990)
Myocardial infarct size after reperfusion therapy: assess-
ment with Gd-DTPA-enhanced MR imaging. Radiology
176:517–521
49. de Roos A, Matheijssen NA, Doornbos J, van Dijkman PR,
van Rugge PR, van der Wall EE (1991) Myocardial infarct
sizing and assessment of reperfusion by magnetic reso-
nance imaging: a review. Int J Card Imaging 7:133–138
50. van Rugge FP, Boreel JJ, van der Wall EE et al (1991)
Cardiac first-pass and myocardial perfusion in normal
subjects assessed by sub-second Gd-DTPA enhanced MR
imaging. J Comput Assist Tomogr 15:959–965
51. van Rugge FP, van der Wall EE, van Dijkman PR,
Louwerenburg HW, de Roos A, Bruschke AV (1992)
Usefulness of ultrafast magnetic resonance imaging in
healed myocardial infarction. Am J Cardiol 70:1233–
1237
52. Holman ER, van Jonbergen HP, van Dijkman PR, van der
Laarse A, de Roos A, van der Wall EE (1993) Comparison
of magnetic resonance imaging studies with enzymatic
indexes of myocardial necrosis for quantification of myo-
cardial infarct size. Am J Cardiol 71:1036–1040
53. Buller VG, van der Geest RJ, Kool MD, van der Wall EE,
de Roos A, Reiber JH (1997) Assessment of regional left
ventricular wall parameters from short axis magnetic res-
onance imaging using a three-dimensional extension to the
improved centerline method. Invest Radiol 32:529–539
54. van der Wall EE, Bax JJ (2008) Late contrast enhancement
by CMR: more than scar? Int J Cardiovasc Imaging
24:609–611
55. Nijveldt R, Beek AM, Hirsch A et al (2008) ‘No-reflow’
after acute myocardial infarction: direct visualisation of
microvascular obstruction by gadolinium-enhanced CMR.
Neth Heart J 16:179–181
56. Ypenburg C, Roes SD, Bleeker GB et al (2007) Effect of
total scar burden on contrast-enhanced magnetic resonance
imaging on response to cardiac resynchronization therapy.
Am J Cardiol 99:657–660
57. Matheijssen NA, de Roos A, van der Wall EE et al (1991)
Acute myocardial infarction: comparison of T2-weighted
and T1-weighted gadolinium-DTPA enhanced MR imag-
ing. Magn Reson Med 17:460–469
58. Innocenti F, Agresti C, Baroncini C et al (2010) Prognostic
value of dobutamine stress echocardiography in diabetic
patients. Int J Cardiovasc Imaging. 2010 Feb 14. [Epub
ahead of print]
59. Giri S, Shaw LJ, Murthy DR et al (2002) Impact of dia-
betes on the risk stratification using stress single-photon
emission computed tomography myocardial perfusion
imaging in patients with symptoms suggestive of coronary
artery disease. Circulation 105:32–40
60. Scholte AJ, Schuijf JD, Kharagjitsingh AV et al (2008)
Different manifestations of coronary artery disease by
stress SPECT myocardial perfusion imaging, coronary
calcium scoring, and multislice CT coronary angiography
in asymptomatic patients with type 2 diabetes mellitus. J
Nucl Cardiol 15:503–509
61. Scholte AJ, Schuijf JD, Kharagjitsingh AV et al (2009)
Prevalence and predictors of an abnormal stress myocar-
dial perfusion study in asymptomatic patients with type 2
diabetes mellitus. Eur J Nucl Med Mol Imaging 36:567–
575
62. Young LH, Wackers FJ, Chyun DA et al (2009) Cardiac
outcomes after screening for asymptomatic coronary artery
disease in patients with type 2 diabetes: the DIAD study: a
randomized controlled trial. JAMA 301:1547–1555
942 Int J Cardiovasc Imaging (2011) 27:939–942
123
